RS3PE with malignancy (n = 8) | RS3PE without malignancy (n = 38) | OA (n = 15) | EORA (n = 14) | F/t | P | |
---|---|---|---|---|---|---|
Flt-1 (ng/mL) | 7.38±2.64 | 6.14±2.25 | 5.96±1.53 | 5.59±1.67 | 1.321 | 0.275 |
PlGF (ng/mL) | 6.14 (4.436, 6.58) | 5.99 (4.45, 7.29) | 5.61(4.74, 6.6) | 4.81 (4.48, 7.15) | 0.745 | 0.863 |
Tie-2 (ng/mL) | 8.99±2.34 | 9.92±2.89 | 11.26±2.72 | 8.47±2.41 | 2.816 | 0.045 |
VEGF (ng/mL) | 168.41 (90.86, 327.61) | 83.15 (50.34, 200.11) | 156.24 (117.94, 239.03) | 71.68 (40.74, 234.95) | 4.144 | 0.246 |
VEGF-C (ng/mL) | 3.76 (1.69, 7.58) | 4.75 (3.72, 9.79) | 6.57 (5.45, 7.82) | 5.31 (3.87, 6.46) | 3.281 | 0.350 |
VEGF-D (ng/mL) | 18.40 (14.86, 30.31) | 31.92 (26.88, 46.75) | 26.43 (23.64, 36.74) | 24.98 (17.56, 34.74) | 10.433 | 0.015 |
bFGF (ng/mL) | 14.21 (7.52, 23.18) | 4.32 (2.88, 7.42)▲ | 3.23 (1.96, 5.59)▲ | 3.20 (2.20, 5.30)▲ | 15.861 | 0.001 |
MMP-3 (ng/mL) | 24.74 (17.96, 51.67) | 36.08 (19.01, 54.34) | 22.03 (14.84, 25.57) | 33.31 (15.86, 41.44) | 5.346 | 0.148 |
MMP-1 (ng/mL) | 4.98 (3.80, 7.50) | 3.93 (1.94, 7.73) | 2.90 (1.72, 4.50) | 5.80 (3.37, 10.73) | 5.472 | 0.140 |
MMP-7 (ng/mL) | 2.11 (1.55, 5.02) | 2.86 (1.99, 3.40) | 2.68 (1.64, 4.16) | 3.06 (2.02, 5.03) | 0.864 | 0.834 |
TRAIL (pg/mL) | 82.28 (57.26, 121.38) | 93.86 (75.98, 140.34) | 98.56 (84.51, 114.28) | 89.96 (61.04, 124.94) | 2.324 | 0.508 |
Mesothelin (ng/mL) | 25.65 (17.81, 34.84) | 24.10 (17.89, 30.54) | 27.20 (15.40, 30.27) | 21.96 (18.94, 28.50) | 0.688 | 0.876 |